Faktori rizika za kardiovaskularne bolesti i ishod reperfuzione terapije nakon infarkta miokarda sa ST elevacijom
Authors: Lozo Srdjan 
Published: July 2014

&lt;p&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 507.885px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.12556);&quot; role=&quot;presentation&quot;&gt;Uvod&lt;/span&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 360.256px; top: 507.885px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.10768);&quot; role=&quot;presentation&quot;&gt;. Faktori rizika za nastanak kardiovaskularnih bolesti (KVB) mogu se&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 527.885px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.11399);&quot; role=&quot;presentation&quot;&gt;podijeliti na nepromjenljive i promjenljive. Osnovni oblik terapije akutnog&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 547.885px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.09693);&quot; role=&quot;presentation&quot;&gt;infarkta sa ST elevacijom (STEMI) je reperfuziona terapija. Nema dovoljno&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 567.885px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.10195);&quot; role=&quot;presentation&quot;&gt;podataka da li prethodni faktori rizika utiču na uspjeh reperfuzione terapije.&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 587.885px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.07658);&quot; role=&quot;presentation&quot;&gt;Procjena uspje&amp;scaron;nosti reperfuzione terapije se može lako izvr&amp;scaron;iti određivanjem&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 607.885px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.05367);&quot; role=&quot;presentation&quot;&gt;stepena rezolucije ST segmenta. Cilj rada je bio da utvrdi povezanost pojedinih&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 627.885px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.11012);&quot; role=&quot;presentation&quot;&gt;faktora rizika za nastanak kardiovaskularnih bolesti i stepena rezolucije ST&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 647.885px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.10008);&quot; role=&quot;presentation&quot;&gt;segmenta poslije primjene reperfuzionih procedura nakon STEMI.&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 677.334px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.13798);&quot; role=&quot;presentation&quot;&gt;Metode&lt;/span&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 376.482px; top: 677.334px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.04959);&quot; role=&quot;presentation&quot;&gt;. U studiju je uključeno 156 bolesnika, od kojih su 134 liječena primar&lt;/span&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 868.486px; top: 677.334px; font-size: 16.6667px; font-family: serif;&quot; role=&quot;presentation&quot;&gt;-&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 697.334px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.11747);&quot; role=&quot;presentation&quot;&gt;nom perkutanom koronarnom intervencijom (PPCI), a 22 bolesnika fibrin&lt;/span&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 868.461px; top: 697.334px; font-size: 16.6667px; font-family: serif;&quot; role=&quot;presentation&quot;&gt;-&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 717.334px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.13147);&quot; role=&quot;presentation&quot;&gt;olitičkom terapijom. Bolesnicima su prilikom prijema uzimani standardni&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 737.334px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.11936);&quot; role=&quot;presentation&quot;&gt;anamnestički podaci sa osvrtom na prisustvo prethodnih faktora rizika. Na&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 757.334px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.15282);&quot; role=&quot;presentation&quot;&gt;osnovu nalaza standardnog 12-kanalnog EKG registrovanog pri prijemu&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 777.334px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.11236);&quot; role=&quot;presentation&quot;&gt;bolesnika i EKG poslije 90 &amp;plusmn; 15 min nakon zavr&amp;scaron;etka reprefuzione terapije&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 797.334px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.09384);&quot; role=&quot;presentation&quot;&gt;određivan je stepen rezolucije ST segmenta po metodologiji Schrodera i sar.&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 817.334px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.14237);&quot; role=&quot;presentation&quot;&gt;Pacijenti su podijeljeni u 3 grupe prema veličini rezolucije ST segmenta:&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 837.334px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.06595);&quot; role=&quot;presentation&quot;&gt;kompletna rezolucija ST segmenta (&amp;gt;70%); parcijalna rezolucija ST segmenta&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 857.334px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.06304);&quot; role=&quot;presentation&quot;&gt;(30-70%); bez rezolucije ST segtmenta (&amp;lt;30%).&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 886.784px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.15342);&quot; role=&quot;presentation&quot;&gt;Rezultati&lt;/span&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 387.99px; top: 886.784px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.09268);&quot; role=&quot;presentation&quot;&gt;. Nije utvrđena statistički značajna razlika u učestalosti većine kar&lt;/span&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 868.461px; top: 886.784px; font-size: 16.6667px; font-family: serif;&quot; role=&quot;presentation&quot;&gt;-&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 906.784px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.11103);&quot; role=&quot;presentation&quot;&gt;diovaskularnih faktora rizika među podgrupama bolesnika sa kompletnom,&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 926.784px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.08162);&quot; role=&quot;presentation&quot;&gt;parcijalnom i bez rezolucije ST segmenta (pol: p=0,452; porodična predispo&lt;/span&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 868.468px; top: 926.784px; font-size: 16.6667px; font-family: serif;&quot; role=&quot;presentation&quot;&gt;-&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 946.784px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.07611);&quot; role=&quot;presentation&quot;&gt;zicija: p=0,849; hiperlipidemija: p=0,92; pu&amp;scaron;enje: p=0,651; prethodni infarkt:&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 966.783px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.05264);&quot; role=&quot;presentation&quot;&gt;p=0,603; diabetes mellitus tip 2: p=0,147). Značajna razlika u učestalosti među&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 986.783px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.09493);&quot; role=&quot;presentation&quot;&gt;grupama postoji za hipertenziju (p=0,041).&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 1016.23px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.15279);&quot; role=&quot;presentation&quot;&gt;Zaključak&lt;/span&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 395.39px; top: 1016.23px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.1071);&quot; role=&quot;presentation&quot;&gt;. Prisustvo hipertenzije kao faktora rizika za nastanak KVB utiče&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 1036.23px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.10498);&quot; role=&quot;presentation&quot;&gt;na stepen rezolucije ST segmenta poslije primijenjene reperfuzione terapije&lt;/span&gt;&lt;br role=&quot;presentation&quot; /&gt;&lt;span dir=&quot;ltr&quot; style=&quot;left: 318.573px; top: 1056.23px; font-size: 16.6667px; font-family: serif; transform: scaleX(1.09163);&quot; role=&quot;presentation&quot;&gt;nakon STEMI, odnosno na uspje&amp;scaron;nost ove terapije.&lt;/span&gt;&lt;/p&gt;